IP Library Granted Patent US 7,148,030
Granted Patent B2
US 7,148,030 · App. 10/356,665 · Granted Dec 12, 2006

Bioluminescent protease assay

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,148,030
App. No.
10/356,665
Granted
Dec 12, 2006
Kind
B2
Abstract

A sensitive bioluminescent assay to detect proteases including caspases, trypsin and tryptase is provided.

Claims (33)

1. A luminescent assay method to detect one or more caspases, comprising:

a) contacting a sample suspected of having one or more caspases with a mixture comprising luciferase and an amino-modified aminoluciferin or a carboxy-terminal protected derivative thereof, wherein the modification is the covalent linkage of a substrate for the caspase to the amino group of aminoluciferin or the derivative thereof via a peptide bond, and wherein the caspase cleaves the substrate at the peptide bond; and

b) detecting luminescence in the sample, wherein the luminescent assay is more sensitive than a corresponding assay with a conjugate comprising a fluorophore covalently linked to the substrate or a functional equivalent thereof.

2. A luminescent assay method to detect a protease that specifically cleaves a substrate comprising aspartate, comprising:

a) contacting a sample suspected of having one or more aspartate-specific proteases with a mixture comprising luciferase and an amino-modified aminoluciferin or a carboxy-terminal protected derivative thereof, wherein the modification is the covalent linkage of a substrate comprising aspartate to the amino group of aminoluciferin or the derivative thereof via a peptide bond, and wherein the protease cleaves the substrate at the peptide bond; and

b) detecting luminescence in the sample, wherein the luminescent assay is more sensitive than a corresponding assay with a conjugate comprising a fluorophore covalently linked to the substrate or a functional equivalent thereof.

3. The method of claim 1 or 2 further comprising correlating luminescence with caspase or aspartate-specific protease concentration or activity.

4. The method of claim 1 or 2 which detects a caspase other than caspase 3 or caspase 7.

5. The method of claim 1 or 2 which detects caspase 3 or caspase 7.

6. The method of claim 5 which detects at least 0.2 microunits of caspase.

7. The method of claim 1 or 2 wherein the substrate comprises X 1 -X 2 -X 3 -D, wherein X 1 is Y, D, L, V, I, A, W, or P; X 2 is V or E; and X 3 is any amino acid.

8. The method of claim 6 wherein X 3 is A, V, H, I, or T.

9. The method of claim 1 or 2 wherein the substrate comprises DEVD (SEQ ID NO:1).

10. The method of claim 1 or 2 wherein the substrate comprises YVAD (SEQ ID NO:2).

11. The method of claim 1 or 2 wherein the substrate comprises LEHD (SEQ ID NO:3).

12. The method of claim 1 or 2 which is at least 2 times more sensitive than a corresponding assay with a conjugate comprising rhodamine-110 covalently linked to the substrate.

13. The method of claim 1 or 2 wherein the sample is a cell lysate.

14. The method of claim 13 wherein the cells are treated with an apoptosis inducing agent prior to lysis.

15. The method of claim 1 or 2 wherein the sample comprises intact cells.

16. The method of claim 15 wherein the cells are treated with an apoptosis inducing agent.

17. The method of claim 1 or 2 wherein the luciferase is a thermostable luciferase.

18. The method of claim 1 wherein the carboxy-terminal protected derivative thereof is a compound of formula (I):

wherein R is a peptide that is a substrate for caspase, which is linked to the remainder of the compound of formula (I) through its C-terminus forming a peptide (amide) bond; and R′ is H or a suitable carboxy protecting group, or a suitable salt thereof.

19. The method of claim 18 wherein R′ is (C 1 –C 6 )alkyl, phenyl or benzyl.

20. The method of claim 2 wherein the carboxy-terminal protected derivative thereof is a compound of formula (I):

wherein R is a peptide that is linked to the remainder of the compound of formula (I) through an aspartate group at the C-terminus of the peptide forming a peptide bond; and R′ is H or a suitable carboxy protecting group, or a suitable salt thereof.

21. The method of claim 18 or 20 wherein R′ is (C 1 –C 6 )alkyl.

22. The method of claim 18 or 20 wherein R′is methyl, ethyl, propyl, or tert-butyl.

23. The method of claim 18 or 20 wherein R comprises X 1 -X 2 -X 3 -D, wherein X 1 is Y, D, L, V, I, A, W, or P; X 2 is V or E; and X 3 is any amino acid.

24. The method of claim 23 wherein X 3 is A, V, H, I, or T.

25. The method of claim 23 wherein R comprises DEVD (SEQ ID NO:1).

26. The method of claim 23 wherein R comprises YVAD (SEQ ID NO:2).

27. The method of claim 23 wherein R comprises LEHD (SEQ ID NO:3).

Assignments (2)
SECURITY INTEREST Recorded Apr 3, 2019
From: PROMEGA CORPORATION; PROMEGA BIOSCIENCES, LLC; TERSO SOLUTIONS, INC.; ORION SEVEN, LLC; PROMEGA AVIATION LLC
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 048790/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2003
From: O'BRIEN, MARTHA; WOOD, KEITH V.; KLAUBERT, DIETER; DAILY, WILLIAM
To: PROMEGA CORPORATION
Reel/Frame 014173/0060 →